FDA estimates the burden of this collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN[1]

21 CFR Part	Form	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
710	FDA 2511	50	1	50	0.4	20

[1] There are no capital costs or operating and maintenance costs associated with this collection of information.

The burden estimates are based on past experience and on discussions with registrants during routine communications. FDA receives an average of 50 registration submissions annually. There has been no change over the past 13 years in the number of submissions of Form FDA 2511 or in the time it takes to complete this form.

Dated: April 14, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–10405 Filed 4–20–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–0148]

International Drug Scheduling; Convention on Psychotropic Substances; Dihydroetorphine, Ephedrine, and Remifentanil; Isomers of Psychotropic Substances

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of March 18, 1998 (63 FR 13258). The document announced an upcoming World Health Organization review of three substances. The document was published with an error. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Nicholas P. Reuter, Office of Health Affairs (HFY–20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1696, E-mail: NReuter@bangate.fda.gov.

In FR Doc. 98–6910, beginning on page 13258 in the **Federal Register** of Wednesday, March 18, 1998, the following correction is made:

1. On page 13259, in the first column, in the fourth full paragraph, the second sentence ''Remifentanil is approved in the United States as an anesthetic for use in animals and is controlled domestically as a narcotic in schedule II of the CSA.'' is corrected to read as follows: ''Remifentanil is approved in the United States as an anesthetic and is controlled domestically as a narcotic in schedule II of the CSA.''

Dated: April 14, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–10404 Filed 4–20–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Science Advisory Board to the National Center for Toxicological Research; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Science Advisory Board to the National Center for Toxicological Research (NCTR).

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on May 6, 1998, 9 a.m. to 5 p.m., and May 7, 1998, 9 a.m. to 11 a.m.

Location: NCTR, Jefferson, AR.

Contact Person: Ronald F. Coene, NCTR (HFT–10), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–6696, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12559. Please call the Information Line for up-to-date information on this meeting.

Agenda: The board will be presented with draft reports on evaluations of three of NCTR's programs in Information Technology, Biometry and Risk Assessment, and Neurotoxicology for their review, discussion, and approval. The draft reports are the products of three site visit teams who conducted onsite reviews over the last 9 months. The staff from these programs will provide a preliminary response to the issues raised and recommendations made. A progress report will be presented to the board on the recommendations it made at its last meeting on NCTR's Estrogen Knowledge Base project. Also, there will be a Center Director's update.

Procedure: On May 6, 1998, from 9 a.m. to 5 p.m., and May 7, 1998, from 9 a.m. to 11 a.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by April 17, 1998. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 m., on May 7, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before April 17, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations. On May 7, 1998, from 1 p.m. to 2:30 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). This portion of the meeting will be closed to permit discussion of information concerning individuals associated with the research programs at NCTR.

The Commissioner approves the scheduling of meetings at locations outside of the Washington, DC, area on the basis of the criteria of 21 CFR 14.22 of FDA's regulations relating to public advisory committees.